Documents

NCI-H69/LX10

96042331

Pricing and availability is not currently available.

biological source

human lung

growth mode

Aggregates in suspension

karyotype

Not specified

morphology

Not specified

products

Not specified

receptors

Not specified

application(s)

cell culture | mammalian: suitable

relevant disease(s)

cancer

shipped in

dry ice

storage temp.

−196°C

Related Categories

Cell Line Origin

Human small cell lung cancer, drug-resistant

Cell Line Description

The drug-resistant cell line NCI-H69/LX10 has been derived from the parent line NCI-H69 (ECACC No 91091802). It is recommended to culture the cells without drug upon resuscitation; add doxorubicine once growth is fully established.

Application

Drug-resistance studies

Culture Medium

RPMI 1640 + 2mM Glutamine + 1.0 μg/ml doxorubicine + 10% Foetal Bovine Serum (FBS).

Subculture Routine

Maintain cultures between 3-9 x 100,000 cells/ml; 5% CO2, 37ºC; resuscitate in drug-free medium and add drug after growth has been established.

Other Notes

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.

RIDADR

NONH for all modes of transport

Certificate of Analysis
Certificate of Origin

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.